血浆游离RNA作为结直肠癌生物标志物的研究进展  

The research progress of cell free RNA as a biomarker for colorectal cancer

作　　者：马静[1] 冯泽慧 党苗 邢金良 方芳 刘洋 MA Jing;FENG Zehui;DANG Miao;XING Jinliang;FANG Fang;LIU Yang(Yanbian University,Jilin Yanji 133000,China;Air Force Medical University,Shaanxi Xi'an 710032,China;Tangdu Hospital,Air Force Medical University,Shaanxi Xi'an 710038,China.)

机构地区：[1]延边大学,吉林延吉133000 [2]空军军医大学,陕西西安710032 [3]空军军医大学唐都医院,陕西西安710038

出　　处：《现代肿瘤医学》2024年第14期2633-2637,共5页Journal of Modern Oncology

基　　金：国家自然科学基金重点项目(编号:81830070)。

摘　　要：近年来,血浆游离RNA成为了一种新型且极具吸引力的液体活检标志物。随着测序技术的快速发展,人们对于血浆游离RNA的认识愈加全面。转录组测序技术的发展使血浆游离RNA能够提供多种靶基因的表达水平、RNA的结构及序列等重要信息。此外,肿瘤特异性转录本的过表达能够增加血浆中肿瘤来源的RNA信号,克服了由于循环肿瘤DNA数量少而导致的局限性。该文的目的是对血浆游离RNA及其作为结直肠癌诊断、预后、预测和耐药生物标志物的现状进行综述。最后,我们讨论了血浆游离RNA在临床实际应用中的局限性及未来发展趋势。In recent years,cell free RNA has become a novel and attractive liquid biomarker.With the rapid development of sequencing technology,cell free RNA is much more understood comprehensively.Cell free RNA can provide important information such as the expression levels of multiple target genes,RNA structure and sequence by RNA sequencing.In addition,the overexpression of cancer-specific transcripts increases tumor-derived RNA signals in plasma,which overcomes limitations caused by low quantities of circulating tumor DNA.The purpose of this article is to review of current knowledge regarding circulating tumor RNA(ctRNA)and their status as biomarkers to address the diagnosis,prognosis,prediction,and drug resistance of colorectal cancer.Finally,we discuss the limitations and future perspectives of cell free RNA in clinical applications.

关 键 词：肿瘤标志物 血浆游离RNA 结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]